iBio, Inc. (IBIO) P/E Ratio History
Historical price-to-earnings valuation from 2014 to 2014
Loading P/E history...
IBIO Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, iBio, Inc. (IBIO) trades at a price-to-earnings ratio of -0.9x, with a stock price of $1.64 and trailing twelve-month earnings per share of $-0.25.
The current P/E is 102% below its 5-year average of 53.2x. Over the past five years, IBIO's P/E has ranged from a low of 43.4x to a high of 65.3x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, IBIO trades at a 104% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, IBIO trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our IBIO DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
IBIO P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $2B | 14.1 | - | -26% | |
| $8B | 25.5 | 1.11Best | -25% | |
| $2B | 3.6Lowest | - | +307%Best | |
| $490M | 28.3 | 2.12 | +188% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
IBIO Historical P/E Data (2014–2014)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2014 Q4 | Mon Jun 30 2014 00:00:00 GM | $2100.00 | $42.21 | 49.8x | -6% |
| FY2014 Q3 | Mon Mar 31 2014 00:00:00 GM | $2700.00 | $41.35 | 65.3x | +23% |
| FY2014 Q2 | $1700.00 | $39.19 | 43.4x | -18% | |
| FY2014 Q1 | Mon Sep 30 2013 00:00:00 GM | $2150.00 | $39.56 | 54.3x | +2% |
Average P/E for displayed period: 53.2x
See IBIO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs IBIO Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare IBIO vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonIBIO — Frequently Asked Questions
Quick answers to the most common questions about buying IBIO stock.
Is IBIO stock overvalued or undervalued?
IBIO trades at -0.9x P/E, below its 5-year average of 53.2x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does IBIO's valuation compare to peers?
iBio, Inc. P/E of -0.9x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is IBIO's PEG ratio?
IBIO PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2014-2014.